Danish drugmaker Novo Nordisk A/S said on Monday it is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc, citing concerns about sales of compounded drugs and misleading marketing.
The partnership had been touted as a way to boost obesity-drug sales in the US.
Shares of Hims & Hers plunged 18% in trading before US stock exchanges opened. Novo lost as much as 5% in Copenhagen.
#Novo #Nordisk #exits #obesitydrug #partnership #Hims #cites #compounding #concerns #Company #Business #News
Novo Nordisk, obesity drug, Hims & Hers, Novo Nordisk Shares, Hims & Hers Shares
latest news today, news today, breaking news, latest news today, english news, internet news, top news, oxbig, oxbig news, oxbig news network, oxbig news today, news by oxbig, oxbig media, oxbig network, oxbig news media
HINDI NEWS
News Source
